| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Electrical Pulses (Pulsed Electric Field therapies; PEF) are a bioelectromagnetic modality in oncology that delivers brief, high-voltage (or high-field) pulses to tissue to permeabilize membranes and/or ablate tumors. Clinically relevant categories commonly discussed: -Shorter, bipolar/high-frequency µs waveforms (H-FIRE) are repeatedly shown to reduce or eliminate muscle contractions versus classic monopolar IRE, improving tolerability and potentially reducing need for paralytics. -Nanosecond pulses with fast rise times can overcome membrane charging delays and directly polarize organelles, which is why rise-time engineering becomes a first-order variable for intracellular effects (mitochondria/ER, Ca²⁺, ROS, regulated death programs). -nsPEF / Nano-Pulse Stimulation (NPS) used as irreversible tumor ablation (intracellular emphasis). With ns pulses, fast rise times and short widths can drive intracellular membrane perturbation (not just plasma membrane), shifting biological response vs classic IRE.
In nsPEF systems the main engineering challenge is not current or power, but:
-generating fast rise times
-maintaining transmission line impedance
-preventing pulse distortion at the electrodes
Other important aspects of nsPEF
-mainly an electric field effect:
-Membrane breakdown typically occurs around 0.5–1 V across the membrane,
which corresponds to ~10–50 kV/cm fields in tissue.
-ns pulses terminate before plasma channels develop.
-impedance mismatch and cable dispersion is important
-nsPEF often induces programmed cell death rather than thermal ablation
The hallmark of nsPEF is simultaneous targeting of multiple intracellular pathways, particularly:
-Calcium signaling (Ca²⁺ release)
-Mitochondrial apoptosis (ΔΨm↓, Caspase-9↑, Caspase-3↑)
-ROS stress pathways
Research might show cancer cells have some greater sensitivity to nsPEF,
but nsPEF affects both normal and cancer cells
Electrical Pulses / PEF Oncology Modality — Ranked Mechanistic Axes
|
| Source: |
| Type: |
| ENO2 (Enolase 2) is an enzyme that plays a crucial role in the glycolytic pathway, which is often upregulated in cancer cells, and related to poor prognosis. ENO2 (Enolase 2) is a cytoplasmic enzyme that plays a crucial role in the glycolytic pathway, as I mentioned earlier. It is a key enzyme in the conversion of 2-phosphoglycerate to enolpyruvate, which is then converted to pyruvate. ENOX2 (Enox2), on the other hand, is a cell surface enzyme that is also known as Cytosolic Enolase 2 or ENO2 variant. ENOX2 is a truncated form of ENO2 that lacks the first 96 amino acids of the full-length ENO2 protein. Despite this difference, ENOX2 retains enolase activity and is also involved in the glycolytic pathway. |
| 933- | CUR, | EP, | Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:248 Target#:924 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid